Skip Navigation
Visitor Guideline Update: Due to respiratory virus season, children 12 and under are not permitted to visit patients in multiple settings. Additionally, everyone is required to mask in patient rooms and other designated areas. Learn more.

Vascular Disease

Sanger Heart & Vascular Institute offers access to the latest clinical trials and investigational devices as part of our commitment to delivering the highest quality vascular care.

Recent Highlights

In 2022, we implemented ERAS®, with the goal of improving outcomes while continuing to reduce complications and length of stay for patients undergoing lower extremity revascularization procedures.

Pioneering the Use of Implantable Fish Skin

Kerecis Omega3 SurgiBind implantable fish skin recruits human cells when it is grafted and is gradually converted into living tissue. Sanger is using this innovative approach to help accelerate wound healing in patients with non-healing or slow-healing wounds. Kerecis has designated Sanger a Center of Excellence for this work.

Research and Clinical Trials

Transcarotid stenting has been shown to have excellent outcomes in multiple recent studies. It was recently approved by the FDA for use in normal risk patients. After leading the way and being one of the top enrollers in the ROADSTER 2 trial, Sanger is now part of the ROADSTER 3 trial.

Sanger was one of the highest enrollers in the Percutaneous Deep Vein Arterialization for the Treatment of Late Stage Chronic Limb Threatening Ischemia (PROMISE) II trial and we were selected to be part of the PROMISE III trial.

New Cath Lab

A new, state-of-the-art vascular catheterization lab has opened at Atrium Health Carolinas Medical Center.

  • Outline of planet Earth.

    1st in the world to commercially use the Kerecis Omega3 SurgiBind implantable fish skin graft.

Transcarotid Artery Revascularization

Sanger is a TCAR Center of Excellence (400+ TCAR procedures) and a Peripheral Vascular Center of Excellence.

  • 85

    TCAR Elective Procedures
    2022

    M2S, September 2021 - August 2022


  • 393

    TCAR Total Procedures
    Since Program Inception

    M2S, January 2018 - August 2022


  • 0.0%

    TCAR Elective Procedures
    Stroke Complication Rate

    M2S, September 2021 - August 2022

Lower Extremities


  • 762

    Percutaneous Intervention Procedures
    2022

    M2S, September 2021 - August 2022


  • 3,979

    Percutaneous Intervention Procedures
    Since Program Inception

    M2S, January 2011 - August 2022


  • 0.79%

    Percutaneous Interventions
    In-Hospital Mortality Rate

    M2S, September 2021 - August 2022


  • 1,222

    Revascularization Bypass (infra-inguinal) Procedures
    Since Program Inception

    M2S, January 2011 - August 2022

Carotid Endarterectomy


  • 164

    Elective Procedures
    2022

    M2S, September 2021 - August 2022


  • 1,733

    Elective Procedures
    Since Program Inception

    M2S, January 2011 - August 2022


  • 0.0%

    Elective Procedures
    Stroke Complication Rate

    M2S, September 2021 - August 2022


  • 0.0%

    Elective Procedures
    In-hospital Mortality Rate

    M2S, September 2021 - August 2022

Publications and Presentations

2022 Sanger Heart & Vascular Institute Outcomes and Innovation Report

Close